Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [3599]

New antibody drug enters collaborative phase I/II trial for CLL and non-Hodgkin lymphoma

New antibody drug enters collaborative phase I/II trial for CLL and non-Hodgkin lymphoma

What makes pancreatic cancer so aggressive?

What makes pancreatic cancer so aggressive?

New research unlocks how melanoma can resist newly approved drug combo therapy

New research unlocks how melanoma can resist newly approved drug combo therapy

Study identifies new targeted treatment strategy for some aggressive cancers

Study identifies new targeted treatment strategy for some aggressive cancers

Combined therapy can reduce chance of recurrence in women with small, HER2 breast tumours

Combined therapy can reduce chance of recurrence in women with small, HER2 breast tumours

Scientists develop novel platform for treatment of breast and pancreatic cancer

Scientists develop novel platform for treatment of breast and pancreatic cancer

ASCO GI: Second-line ramucirumab added to standard chemotherapy delays disease progression, extends survival for patients with advanced colorectal cancer

ASCO GI: Second-line ramucirumab added to standard chemotherapy delays disease progression, extends survival for...

Disappointment over NHS England's bowel cancer drug decision

Disappointment over NHS England's bowel cancer drug decision

Afatinib shown to outdo chemo in extending survival in lung cancer with EGFR mutation

Afatinib shown to outdo chemo in extending survival in lung cancer with EGFR mutation

Armed virus shows promise as treatment for pancreatic cancer

Armed virus shows promise as treatment for pancreatic cancer

More from ecancer